Jim Cramer on Recursion: “I Need to See a Proof of Concept Here”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about the stock during the lightning round, Cramer stated:

“I don’t know. It’s been such a dog. It’s been a dog, we had them on, twice the price. It’s done absolutely nothing. I need to see a proof of concept here. I absolutely know that NVIDIA’s in it, but you know what? This, this, this stock has been a bad stock. We need to see something good before I tell you I would put any money in it.”

A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotech company using technology-driven approaches to accelerate drug discovery, with a pipeline targeting conditions such as cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, C. difficile infection, and certain cancers. When a caller asked about the stock during a March episode, Cramer suggested to “hold off.” He said:

“Well, I’ll tell you… I’m reticent to put to, to really just to pull the trigger on Recursion because when they came on it was, it looked like at a good level and since then it’s just been disastrous. We’re going to have to hold off. I gotta meet them face to face and see what’s going on.”

Since the above comment, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stock is down by about 30%.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.